Log in

Urogen Pharma Stock Price, Forecast & Analysis (NASDAQ:URGN)

$26.57
+0.27 (+1.03 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$25.71
Now: $26.57
$26.68
50-Day Range
$20.92
MA: $22.96
$27.65
52-Week Range
$20.72
Now: $26.57
$55.49
Volume104,200 shs
Average Volume165,714 shs
Market Capitalization$555.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:URGN
CUSIPN/A
Phone646-768-9780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.13 million
Book Value$10.09 per share

Profitability

Net Income$-75,660,000.00

Miscellaneous

Employees70
Market Cap$555.31 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.


Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How were Urogen Pharma's earnings last quarter?

Urogen Pharma Ltd (NASDAQ:URGN) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.06) EPS for the quarter, topping the Zacks' consensus estimate of ($1.26) by $0.20. View Urogen Pharma's Earnings History.

When is Urogen Pharma's next earnings date?

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Urogen Pharma.

What price target have analysts set for URGN?

7 equities research analysts have issued twelve-month price objectives for Urogen Pharma's stock. Their forecasts range from $39.00 to $75.00. On average, they expect Urogen Pharma's stock price to reach $54.00 in the next twelve months. This suggests a possible upside of 103.2% from the stock's current price. View Analyst Price Targets for Urogen Pharma.

What is the consensus analysts' recommendation for Urogen Pharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.

What are Wall Street analysts saying about Urogen Pharma stock?

Here are some recent quotes from research analysts about Urogen Pharma stock:
  • 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (10/26/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating after URGN’s investor day as we came away more bullish on UGN-101 as a treatment for LG-UTUC based on commentary from the physician panel which we believe did a good job addressing many of the investor concerns we hear. Additionally, URGN also reported encouraging results for UGN-102 in LG-NMIBC. While we concede LG-UTUC is a small market, we think investors are meaningfully discounting UGN-101’s commercial potential in the face of the clear unmet need for a non-surgical, kidney sparing treatment which was highlighted by the panel. UGN-101 has a high probability of approval, in our view, though we think shares could be range bound until approval/ launch, likely in 1H20." (9/24/2019)

Has Urogen Pharma been receiving favorable news coverage?

Headlines about URGN stock have trended very positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Urogen Pharma earned a media sentiment score of 3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Urogen Pharma.

Who are some of Urogen Pharma's key competitors?

What other stocks do shareholders of Urogen Pharma own?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the folowing people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
  • Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
  • Mr. Stephen Mullennix, Chief Operating Officer
  • Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director

When did Urogen Pharma IPO?

(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are Urogen Pharma's major shareholders?

Urogen Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Shikiar Asset Management Inc. (0.32%), SG Americas Securities LLC (0.24%), Alps Advisors Inc. (0.20%), Bank Hapoalim BM (0.13%), Rhumbline Advisers (0.11%) and California Public Employees Retirement System (0.09%). Company insiders that own Urogen Pharma stock include Mark Schoenberg, Peter P Pfreundschuh, Proquest Investments Iv, LP and Stephen Mullennix. View Institutional Ownership Trends for Urogen Pharma.

Which major investors are selling Urogen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Insider Buying and Selling for Urogen Pharma.

Which major investors are buying Urogen Pharma stock?

URGN stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, California Public Employees Retirement System, Nisa Investment Advisors LLC, Signaturefd LLC, Tower Research Capital LLC TRC , Shikiar Asset Management Inc., Parallel Advisors LLC and Bank Hapoalim BM. View Insider Buying and Selling for Urogen Pharma.

How do I buy shares of Urogen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $26.57.

How big of a company is Urogen Pharma?

Urogen Pharma has a market capitalization of $555.31 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.View Additional Information About Urogen Pharma.

What is Urogen Pharma's official website?

The official website for Urogen Pharma is http://www.urogen.com/.

How can I contact Urogen Pharma?

Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]


MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel